Related Experiment Video

Updated: Jun 27, 2025

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.5K

Antiarrhythmic and Anti-Inflammatory Effects of Sacubitril/Valsartan on Post-Myocardial Infarction Scar

Daina Martínez-Falguera1,2, Júlia Aranyó3,4, Albert Teis3

  • 1ICREC Research Program, Germans Trias i Pujol Research Institute, Barcelona, Spain (D.M.-F., G.F.-C., M.M.-T., I.D.-G., S.R., A.B.-G., C.G.-M.).

Circulation. Arrhythmia and Electrophysiology
|April 26, 2024
PubMed

Insights

Sacubitril/valsartan reduced inflammation and fibrosis in swine hearts after myocardial infarction (MI). This therapy also decreased ventricular tachycardia inducibility, suggesting improved cardiac scar remodeling.

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Medical Science

Background:

  • Sacubitril/valsartan (Sac/Val) is recognized for its efficacy in heart failure management.
  • Limited mechanistic data exist regarding Sac/Val's impact on myocardial scar post-myocardial infarction (MI).

Purpose of the Study:

  • To investigate the effects of Sac/Val on inflammation, fibrosis, and electrophysiological properties in post-MI scar remodeling.
  • To assess Sac/Val's influence on ventricular tachycardia inducibility in a swine model.

Main Methods:

  • Swine models of MI were treated with beta-blocker (BB) alone or BB plus Sac/Val.
  • Systemic immune response, cardiac magnetic resonance imaging, programmed electrical stimulation, and high-density mapping were employed.
  • Histological analysis of myocardial samples was conducted.

Main Results:

  • Sac/Val significantly reduced acute circulating leukocytes and interleukin-12 levels post-MI.
  • Treatment decreased scar mass, border zone mass, and scar collagen I content.
  • Ventricular tachycardia inducibility and deceleration zones were significantly reduced with Sac/Val therapy.

Conclusions:

  • Sac/Val demonstrated a reduction in acute systemic inflammatory markers post-MI.
  • Sac/Val therapy led to reduced total scar and border zone mass.
  • The study concluded that Sac/Val lowers ventricular tachycardia inducibility in post-MI swine models.
Abstract

Keywords:
arrhythmiascardiacfibrosisinflammationmyocardial infarctionsacubitrilvalsartan

More Related Videos

Myocardial Infarction and Functional Outcome Assessment in Pigs12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

27.9K
A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.06:15

A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.

Published on: June 14, 2015

8.7K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
496
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
716
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
980